Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study [Corrigendum]

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886089/
https://www.ncbi.nlm.nih.gov/pubmed/33603341
http://dx.doi.org/10.2147/DDDT.S300704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886089/
https://www.ncbi.nlm.nih.gov/pubmed/33603341
http://dx.doi.org/10.2147/DDDT.S300704

Ejemplares similares